Head to head
Epitalon vs SS-31
Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.
Verdict
Not an either/or
What you are actually choosing between
Before anything else: the dataset lists Epitalon and SS-31 in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.
Both fall into the catch-all "other" class here, which is a bucket rather than a shared mechanism — Epitalon and SS-31 do not work the same way. What links them is the goal they are reached for, not the biology.
The overlap is longevity and recovery and sleep. On this site's goal weighting — an editorial priority score, not a measure of effect size — Epitalon rates 4/5 for longevity and SS-31 rates 4/5. Outside that overlap only SS-31 goes further, carrying weight for metabolic health and neuroprotection; Epitalon's declared goals stop at the overlap.
The evidence
SS-31 sits one step firmer: controlled human trials behind it, without an approval — results across the trial program have been mixed. Epitalon has some human data, but it is small, old, or uncontrolled — the human reports come from one research group and are unreplicated. One tier is a real difference but not a decisive one; it should not on its own settle the choice.
How they differ in practice
Epitalon is a subcutaneous injection and an intramuscular injection; SS-31 is a subcutaneous injection. Both are injected, so route does not decide this one.
SS-31 has a characterized half-life of 2.5 h; Epitalon does not have one published here at all. That asymmetry is worth more than it looks — it usually tracks how much formal pharmacology has been done on a compound.
Committed time differs: Epitalon runs 2 weeks, SS-31 runs 8 weeks.
Risk and difficulty
The contraindication lists are not the same: Epitalon flags active malignancy, which SS-31 does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.
Epitalon is rated intermediate here and SS-31 advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.
Source notes
What the evidence actually says
Verbatim, so you can check the verdict above against what it was built from.
Epitalon
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal extract epithalamin. Human evidence is thin and comes almost entirely from a single Russian research group (Khavinson and colleagues, St Petersburg Institute of Bioregulation and Gerontology); those reports have not been independently replicated outside that group and the longevity and telomerase claims attached to it should be treated as unproven. It is not an approved medicine in the US or EU. Dosing convention is a short pulsed course rather than continuous use: typically 5-10 mg daily for 10-20 days, repeated once or twice a year. The plasma half-life is very short (reported in minutes), so no meaningful hourly figure is listed here. The active-malignancy flag is precautionary, on the theoretical basis of the claimed telomerase activation.
SS-31 (Elamipretide)
A mitochondria-targeting tetrapeptide that binds cardiolipin on the inner mitochondrial membrane. Unlike most research peptides it has a real human trial record: Stealth BioTherapeutics has run randomized phase 2 and phase 3 studies in primary mitochondrial myopathy (the MMPOWER program), Barth syndrome, dry age-related macular degeneration and heart failure, most using 40 mg subcutaneously once daily. Results have been mixed — several trials, including MMPOWER-3, missed their primary endpoints — and it is not an approved medicine. The 40 mg upper bound is the trial dose; community protocols typically run far lower at 5-10 mg daily, which is the typical value shown. Plasma half-life after subcutaneous dosing is short, roughly 2-3 hours.
Side by side
The numbers
| Attribute | Epitalon | SS-31 |
|---|---|---|
| Class | Other | Other |
| Routes | Subcutaneous, Intramuscular | Subcutaneous |
| Dose range | 5 mg–10 mg (typical 10 mg) | 5 mg–40 mg (typical 10 mg) |
| Frequency | Once daily | Once daily |
| Half-life | Not characterized | 2.5 h |
| Cycle length | 2 weeks | 8 weeks |
| Experience | Intermediate | Advanced |
| Evidence | Limited human data | Controlled human trials |
| Contraindications |
|
|
| Side effects |
|
|
Turn a typical dose into a mark on the syringe: EpitalonSS-31
Goals
Where they overlap, and where they do not
| Goal | Epitalon | SS-31 |
|---|---|---|
| longevity | Epitalon: 4/5 | SS-31: 4/5 |
| recovery and sleep | Epitalon: 3/5 | SS-31: 3/5 |
| metabolic healthone only | Epitalon: — | SS-31: 3/5 |
| neuroprotectionone only | Epitalon: — | SS-31: 3/5 |
| immune supportone only | Epitalon: 2/5 | SS-31: — |
| inflammationone only | Epitalon: — | SS-31: 2/5 |
| skin and hairone only | Epitalon: 2/5 | SS-31: — |
They overlap on 2 goals and diverge on 5. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.
Next
Go deeper
Related
Other comparisons with these two
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.